Ratings NOVAREX Co.,Ltd.

Equities

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-04-25 EDT			5-day change	1st Jan Change
9,460 ^KRW	-0.73%		+0.21%	-22.08%

03-21	NOVAREX Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	NOVAREX Co.,Ltd.(KOSDAQ:A194700) dropped from S&P Global BMI Index	CI

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
The company shows low valuation levels, with an enterprise value at 507.36 times its sales.
The company's share price in relation to its net book value makes it look relatively cheap.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Historically, the company has been releasing figures that are above expectations.

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
NOVAREX CO.,LTD.	-22.08%	122M		-
ZHEJIANG NHU COMPANY LTD.	+8.20%	7.78B		D+
BELLRING BRANDS, INC.	+0.34%	7.38B		C-
CSPC INNOVATION PHARMACEUTICAL CO., LTD.	+10.20%	6.52B		-
BYHEALTH CO., LTD	-8.10%	3.67B		D
XIAMEN KINGDOMWAY GROUP COMPANY	-14.57%	1.17B	-	-
SIRIO PHARMA CO., LTD.	+8.34%	934M		-
HERBALIFE LTD.	-42.27%	879M		B+
USANA HEALTH SCIENCES, INC.	-18.90%	836M		C+
JAMIESON WELLNESS INC.	-16.45%	802M		C+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality